Diminished Expression of Complement Regulatory Proteins on Peripheral Blood Cells from Systemic Lupus Erythematosus Patients

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2012 Jul 5

PMID 22761633

Citations 13

Authors

Ana Paula Alegretti

Laiana Schneider

Amanda Kirchner Piccoli

Odirlei Andre Monticielo

Priscila Schmidt Lora

Joao Carlos Tavares Brenol

Ricardo Machado Xavier

Affiliations

Soon will be listed here.

Abstract

CD55, CD59, CD46, and CD35 are proteins with complement regulatory (Creg) properties that ensure cell and tissue integrity when this system is activated. The aim of this study was to evaluate the Creg expression on peripheral blood cells from SLE patients and its association with cytopenia and disease activity. Flow cytometric analyses were performed on blood cells from 100 SLE patients and 61 healthy controls. Compared with healthy controls, we observed in SLE patients with lymphopenia and neutropenia decreased expression of CD55, CD59, and CD46 (P < 0.05). In SLE patients with anemia, CD59 and CD35 were decreased on red blood cells. Furthermore, there was a negative correlation between CD55 and CD59 on neutrophils and the disease activity. The results suggest there is an altered pattern of Creg expression on the peripheral blood cells of SLE patients, and the expression is correlated with disease activity and/or with activation of the complement system.

Citing Articles

A Review of the Knops Blood Group System.

Ma X, Zhao Z, Zhang Y, Li L, Zhong J Clin Appl Thromb Hemost. 2024; 30:10760296241309638.

PMID: 39706812 PMC: 11662384. DOI: 10.1177/10760296241309638.

Dysregulation of immunity in COVID-19 and SLE.

Hejazian S, Hejazian S, Farnood F, Azar S Inflammopharmacology. 2022; 30(5):1517-1531.

PMID: 36028612 PMC: 9417079. DOI: 10.1007/s10787-022-01047-2.

Lupus nephritis with corticosteroid responsiveness: molecular changes of CD46-mediated type 1 regulatory T cells.

Tsai Y, Chien J, Chiu Y, Su T, Chiu P, Hsiao K Pediatr Res. 2021; 92(4):1099-1107.

PMID: 34952938 DOI: 10.1038/s41390-021-01882-z.

Expression levels of complement regulatory proteins (CD35, CD55 and CD59) on peripheral blood cells of patients with chronic kidney disease.

Eldewi D, Alhabibi A, El Sayed H, Mahmoud S, El Sadek S, Gouda R Int J Gen Med. 2019; 12:343-351.

PMID: 31571973 PMC: 6754524. DOI: 10.2147/IJGM.S216989.

Reduced Expression of Membrane Complement Regulatory Protein CD59 on Leukocytes following Lung Transplantation.

Michielsen L, Budding K, Drop D, Van de Graaf E, Kardol-Hoefnagel T, Verhaar M Front Immunol. 2018; 8:2008.

PMID: 29403484 PMC: 5786830. DOI: 10.3389/fimmu.2017.02008.

References

Zipfel P, Skerka C . Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009; 9(10):729-40. DOI: 10.1038/nri2620. View

Kim D, Song W . Membrane complement regulatory proteins. Clin Immunol. 2005; 118(2-3):127-36. DOI: 10.1016/j.clim.2005.10.014. View

de Carvalho Lins C, Pereira Crott L, Teixeira J, Barbosa J . Reduced erythrocyte complement receptor type 1 in systemic lupus erythematosus is related to a disease activity index and not to the presence or severity of renal disease. Lupus. 2004; 13(7):517-21. DOI: 10.1191/0961203304lu1053oa. View

Deckert M, Ticchioni M, Bernard A . Endocytosis of GPI-anchored proteins in human lymphocytes: role of glycolipid-based domains, actin cytoskeleton, and protein kinases. J Cell Biol. 1996; 133(4):791-9. PMC: 2120835. DOI: 10.1083/jcb.133.4.791. View

Wilson J, Ratnoff W, Schur P, Fearon D . Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum. 1986; 29(6):739-47. DOI: 10.1002/art.1780290606. View

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

Cohen J, Lutz H, Pennaforte J, Bouchard A, Kazatchkine M . Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1992; 87(3):422-8. PMC: 1554329. DOI: 10.1111/j.1365-2249.1992.tb03013.x. View

Marfurt J, Schwarz S, Sadallah S, Schifferli J . Complement receptor 1 (CD35) on human reticulocytes: normal expression in systemic lupus erythematosus and HIV-infected patients. J Immunol. 1999; 162(12):7549-54. View

Ripoche J, Sim R . Loss of complement receptor type 1 (CR1) on ageing of erythrocytes. Studies of proteolytic release of the receptor. Biochem J. 1986; 235(3):815-21. PMC: 1146760. DOI: 10.1042/bj2350815. View

10.

Gupta R, Ahuja T, Agraharkar M . Disorders of the complement system: an overview. Saudi J Kidney Dis Transpl. 2007; 13(2):119-25. View

11.

Christmas S, de la Mata Espinosa C, Halliday D, Buxton C, Cummerson J, Johnson P . Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes. Immunology. 2006; 119(4):522-8. PMC: 2265819. DOI: 10.1111/j.1365-2567.2006.02467.x. View

12.

Arora M, Arora R, Tiwari S, Das N, Srivastava L . Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus. 2000; 9(2):127-31. DOI: 10.1191/096120300678828154. View

13.

Kawano M, Seya T, Koni I, Mabuchi H . Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1999; 116(3):542-6. PMC: 1905304. DOI: 10.1046/j.1365-2249.1999.00917.x. View

14.

Alahlafi A, Wordsworth P, Wojnarowska F . Activation/inactivation of the classical pathway of complement in non-lesional skin of patients with systemic lupus erythematosus. J Cutan Pathol. 2005; 32(8):537-40. DOI: 10.1111/j.0303-6987.2005.00373.x. View

15.

Walsh L, Tone M, Thiru S, Waldmann H . The CD59 antigen--a multifunctional molecule. Tissue Antigens. 1992; 40(5):213-20. DOI: 10.1111/j.1399-0039.1992.tb02048.x. View

16.

Iida K, Mornaghi R, NUSSENZWEIG V . Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med. 1982; 155(5):1427-38. PMC: 2186668. DOI: 10.1084/jem.155.5.1427. View

17.

Isenberg D, Gladman D . The Systemic Lupus International Collaborating Clinics Group--origins and outcomes. Lupus. 2001; 10(5):375-7. DOI: 10.1191/096120301676101377. View

18.

Zipfel P . Complement and immune defense: from innate immunity to human diseases. Immunol Lett. 2009; 126(1-2):1-7. DOI: 10.1016/j.imlet.2009.07.005. View

19.

Winfield J, Fernsten P, Czyzyk J . Anti-lymphocyte autoantibodies in systemic lupus erythematosus. Trans Am Clin Climatol Assoc. 1996; 108:127-35. PMC: 2376594. View

20.

Bombardier C, Gladman D, Urowitz M, Caron D, Chang C . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35(6):630-40. DOI: 10.1002/art.1780350606. View